TecDAX

EQS-News: PNE AG is on course for a successful year after six encouraging months

Retrieved on: 
Thursday, August 10, 2023

Project pipeline at record level of 16.6 gigawatts; continued expansion of our business

Key Points: 
  • Project pipeline at record level of 16.6 gigawatts; continued expansion of our business
    Cuxhaven, August 10, 2023 – PNE AG closed the first half of 2023 very successfully.
  • The first half of the previous year was characterised by higher electricity prices and a high wind supply.
  • In addition, we were able to increase our project pipeline to a new record level", says Markus Lesser, CEO of PNE AG.
  • The order volume managed by the PNE Group in operations management increased to around 2,710 MW (same period last year: 2,232 MW).

EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

Retrieved on: 
Thursday, August 10, 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023.

Key Points: 
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023.
  • Main growth driver continued to be the business with pharmaceutical radioisotopes, with sales of laboratory equipment also continuing to increase.
  • The Isotope Products segment generated sales of € 65.3 million, € 0.6 million lower than in the first six months of 2022.
  • The Executive Board continues to expect sales of just under € 230 million and net income of around € 25 million.

EQS-News: PNE AG shares also listed on the TecDAX as of today

Retrieved on: 
Tuesday, July 25, 2023

Cuxhaven, July 25, 2023 – The PNE AG share has today been admitted to the TecDAX on an unscheduled basis.

Key Points: 
  • Cuxhaven, July 25, 2023 – The PNE AG share has today been admitted to the TecDAX on an unscheduled basis.
  • This means that PNE, as a Clean Energy Solutions Provider, is now one of the 30 largest German technology companies.
  • The decisive factors for inclusion in the TecDAX are, among other things, the stock market turnover in the past twelve months and the market capitalisation.
  • PNE AG has already been listed in the SDAX since June 2022.

EQS-News: Borussia Dortmund re-admitted to the SDAX

Retrieved on: 
Friday, July 21, 2023

EQS-News: Borussia Dortmund GmbH & Co. KGaA

Key Points: 
  • EQS-News: Borussia Dortmund GmbH & Co. KGaA
    The issuer is solely responsible for the content of this announcement.
  • The shares of Borussia Dortmund GmbH & Co. KGaA (ISIN DE0005493092 / WKN 549309) will be included in the SDAX again with effect from July 25, 2023.
  • In addition to the DAX, the TecDAX and the MDAX, the SDAX belongs to the Prime Standard and the DAX index family.
  • Borussia Dortmund GmbH & Co. KGaA
    21.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma

Retrieved on: 
Saturday, June 10, 2023

The Yttrium-90 labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic against recurrent or refractory primary or isolated secondary central nervous system lymphoma.

Key Points: 
  • The Yttrium-90 labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic against recurrent or refractory primary or isolated secondary central nervous system lymphoma.
  • The phase I/II, dose-finding study will be conducted at the University Hospital in Essen, North Rhine Westphalia, Germany.
  • The study will start after getting final endorsement from the German Radiation Safety Department (BfS),“ commented Dr. Hakim Bouterfa, Chief Medical Officer at Eckert & Ziegler.
  • C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

EQS-News: Krones AG: Krones shares move up to MDAX index

Retrieved on: 
Saturday, June 10, 2023

Deutsche Börse AG announced its decision yesterday evening on the new composition of the DAX index family with effect from 19 June 2023.

Key Points: 
  • Deutsche Börse AG announced its decision yesterday evening on the new composition of the DAX index family with effect from 19 June 2023.
  • The DAX, MDAX, SDAX and TecDAX indices were reviewed on the basis of the Fast Exit and Fast Entry rules.
  • As a result of the periodic review, Krones AG shares are to be promoted from the SDAX to the MDAX index.
  • After five years in the SDAX, Krones is thus returning to the MDAX, Germany’s midcap index comprising 50 companies.

EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

Retrieved on: 
Saturday, May 13, 2023

PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE”

Key Points: 
  • PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE”
    Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809; NASDAQ: EVO) today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023.
  • Evotec’s fully audited Annual Report 2022 “Ahead of the Curve” is now available for downloading on www.evotec.com/financial-reports .
  • Evotec had published preliminary financial results for FY2022 already on 28 March, which have remained unchanged.
  • Evotec also published a qualitative Quarterly Statement for the first quarter of 2023 today.

EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

Retrieved on: 
Thursday, May 11, 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023.

Key Points: 
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023.
  • The significant increase in sales results from the sustainable growth in demand for radioisotopes for pharmaceutical and industrial applications.
  • The main growth driver continues to be the pharmaceutical radioisotope business, and sales of laboratory equipment also increased again.
  • The Executive Board continues to expect sales of just under EUR 230 million and net income of around EUR 25 million.

EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

Retrieved on: 
Tuesday, May 9, 2023

Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.

Key Points: 
  • Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.
  • It would most likely have a large impact on clinical practice and enable a large number of hypertension patients to be cured.
  • The study in Australia is in line with clinical activities in Europe and in the USA, which are supported by PentixaPharm.
  • [68Ga]Ga-PentixaFor is being developed by Eckert & Ziegler's subsidiary PentixaPharm GmbH also as a superiorly sensitive diagnostic for a portfolio of hematooncological malignancies.

EQS-News: Siltronic AG: Dr. Michael Heckmeier takes over as CEO of Siltronic AG - Annual General Meeting approves dividend of EUR 3 per share

Retrieved on: 
Friday, May 5, 2023

After three years in virtual format, Siltronic AG's Annual General Meeting took place in person.

Key Points: 
  • After three years in virtual format, Siltronic AG's Annual General Meeting took place in person.
  • The shareholders followed the proposal of the Executive Board and Supervisory Board to distribute a dividend of EUR 3.00 per share.
  • A total of 69.03 percent of Siltronic AG's share capital was represented at the Annual General Meeting.
  • His successor, Michael Heckmeier, attended the Annual General Meeting as a guest and introduced himself to the shareholders in a short speech.